Figures & data
Figure 1 Illustration of recently approved and novel drugs in clinical trials targeting the different entities of leukemic cells.
Notes: CPX351 causes enhanced DNA damage. Epigenetic drugs target aberrant methylation and acetylation patterns. Immunomodulating molecules nivolumab and flotetuzumab enhance cytotoxic activity of T cells. GO and SL401-based monoclonal antibody therapy selectively targets leukemic cells. FLT3 inhibitors obstruct proliferative signals. Venetoclax targets BCL2 and reduces mitochondrial fitness. IDH inhibitors enasidenib and ivosidenib deplete oncometabolites in leukemic cells and prevent aberrant methylation patterns. Stabilization of mutated p53 by APR246 leads to enhanced tumor-suppressor activity.
Table 1 Select clinical studies on second-generation TKIs with induction therapy
Table 2 Select clinical studies on second-generation TKIs as monotherapy
Table 3 Novel agents in clinical trials
Table 4 Exvivo drug screening–based clinical trials